HK1211036A1 - Recombinant cell surface capture proteins - Google Patents
Recombinant cell surface capture proteinsInfo
- Publication number
- HK1211036A1 HK1211036A1 HK15111643.1A HK15111643A HK1211036A1 HK 1211036 A1 HK1211036 A1 HK 1211036A1 HK 15111643 A HK15111643 A HK 15111643A HK 1211036 A1 HK1211036 A1 HK 1211036A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cell surface
- recombinant cell
- surface capture
- capture proteins
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726040P | 2012-11-14 | 2012-11-14 | |
| PCT/US2013/069993 WO2014078475A2 (en) | 2012-11-14 | 2013-11-14 | Recombinant cell surface capture proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211036A1 true HK1211036A1 (en) | 2016-05-13 |
Family
ID=49679651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111643.1A HK1211036A1 (en) | 2012-11-14 | 2015-11-26 | Recombinant cell surface capture proteins |
| HK16102584.0A HK1214612A1 (zh) | 2012-11-14 | 2016-03-07 | 重組的細胞表面捕捉蛋白 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102584.0A HK1214612A1 (zh) | 2012-11-14 | 2016-03-07 | 重組的細胞表面捕捉蛋白 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9758592B2 (xx) |
| EP (2) | EP2949667B1 (xx) |
| JP (2) | JP6668074B2 (xx) |
| KR (4) | KR20230119245A (xx) |
| CN (2) | CN109485728A (xx) |
| AR (2) | AR093491A1 (xx) |
| AU (3) | AU2013344769B2 (xx) |
| BR (1) | BR112015010758A2 (xx) |
| CA (2) | CA2889541C (xx) |
| DK (2) | DK2949667T3 (xx) |
| EA (2) | EA037546B1 (xx) |
| ES (2) | ES2817373T3 (xx) |
| HK (2) | HK1211036A1 (xx) |
| IL (3) | IL238176B (xx) |
| MX (2) | MX2015006112A (xx) |
| PL (2) | PL2949667T3 (xx) |
| SG (2) | SG11201502629TA (xx) |
| TW (3) | TW202206465A (xx) |
| WO (1) | WO2014078475A2 (xx) |
| ZA (1) | ZA201502538B (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| EP3838923B1 (en) | 2012-08-24 | 2024-05-01 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| TW202206465A (zh) | 2012-11-14 | 2022-02-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| EA038931B9 (ru) * | 2014-11-20 | 2022-02-18 | Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. | Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений |
| AU2016261854B2 (en) | 2015-05-12 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Multimeric protein purity determination |
| IL258009B2 (en) | 2015-09-15 | 2024-03-01 | Univ Texas | Antibodies that bind receptors on T cells (TCR) and their use |
| TW201803981A (zh) | 2016-04-20 | 2018-02-01 | 再生元醫藥公司 | 用於以使用增強表現基因座爲基礎製造抗體之組成物及方法 |
| MX2018012868A (es) | 2016-04-20 | 2019-03-11 | Regeneron Pharma | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. |
| SG11201811559WA (en) | 2016-06-27 | 2019-01-30 | Univ California | Cancer treatment combinations |
| CA3056249A1 (en) | 2017-03-24 | 2018-09-27 | Lankenau Institute For Medical Research | Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas |
| CN107177613A (zh) * | 2017-07-18 | 2017-09-19 | 哈尔滨紫霞生物科技有限公司 | 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法 |
| TW201925233A (zh) * | 2017-12-07 | 2019-07-01 | 日商中外製藥股份有限公司 | 抗體、用於在樣品中偵測或捕捉多肽的組成物以及在樣品中偵測或捕捉多肽的方法 |
| EP3856910A4 (en) * | 2018-09-24 | 2022-09-28 | Merck Sharp & Dohme Corp. | EXPRESSION VECTORS FOR EUKARYOT EXPRESSION SYSTEMS |
| US20220144916A1 (en) * | 2019-02-12 | 2022-05-12 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151350A (en) * | 1982-10-27 | 1992-09-29 | Repligen Corporation | Cloned genes encoding recombinant protein a |
| US5635354A (en) | 1991-01-09 | 1997-06-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system |
| US6399368B1 (en) | 1992-01-17 | 2002-06-04 | Board Of Regents, The University Of Texas System | Secretion of T cell receptor fragments from recombinant Escherichia coli cells |
| US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
| AU679949B2 (en) | 1992-10-21 | 1997-07-17 | Stefan Miltenyi | Direct selection of cells by secretion product |
| US6482655B1 (en) | 1993-07-23 | 2002-11-19 | University Of Utah Research Foundation | Immunoassay procedure utilizing fluorogenic tracer antigens |
| US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
| US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| BRPI9715219B8 (pt) | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6232066B1 (en) | 1997-12-19 | 2001-05-15 | Neogen, Inc. | High throughput assay system |
| WO1999058977A1 (en) | 1998-05-11 | 1999-11-18 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
| DE69931776T2 (de) | 1998-05-20 | 2007-05-16 | Chugai Seiyaku K.K. | Verfahren zur klonierung von genen |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| DE19900635A1 (de) | 1999-01-11 | 2000-07-13 | Deutsches Krebsforsch | Selektion von monoklonalen Antikörpern |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US20140072980A1 (en) | 2001-01-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US20140072979A1 (en) | 2001-01-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| ES2309167T3 (es) | 2001-02-19 | 2008-12-16 | Merck Patent Gmbh | Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida. |
| PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
| EP2093286B1 (en) | 2001-10-01 | 2013-02-27 | Dyax Corporation | Multi-chain eukaryotic display vectors and uses thereof |
| EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| ES2527297T3 (es) * | 2007-07-31 | 2015-01-22 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos para CD20 humano y método para utilizar los mismos |
| CN103833855A (zh) * | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
| CA2785414C (en) | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| TW202206465A (zh) | 2012-11-14 | 2022-02-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
-
2013
- 2013-11-13 TW TW110138498A patent/TW202206465A/zh unknown
- 2013-11-13 TW TW107128129A patent/TWI745610B/zh active
- 2013-11-13 TW TW102141304A patent/TWI675044B/zh active
- 2013-11-14 ES ES13798483T patent/ES2817373T3/es active Active
- 2013-11-14 CA CA2889541A patent/CA2889541C/en active Active
- 2013-11-14 KR KR1020237026105A patent/KR20230119245A/ko not_active Application Discontinuation
- 2013-11-14 EA EA201590928A patent/EA037546B1/ru unknown
- 2013-11-14 WO PCT/US2013/069993 patent/WO2014078475A2/en active Application Filing
- 2013-11-14 BR BR112015010758A patent/BR112015010758A2/pt not_active Application Discontinuation
- 2013-11-14 AU AU2013344769A patent/AU2013344769B2/en active Active
- 2013-11-14 DK DK15172149.5T patent/DK2949667T3/da active
- 2013-11-14 KR KR1020217003226A patent/KR20210014766A/ko not_active IP Right Cessation
- 2013-11-14 DK DK13798483.7T patent/DK2920208T3/da active
- 2013-11-14 PL PL15172149T patent/PL2949667T3/pl unknown
- 2013-11-14 ES ES15172149T patent/ES2805526T3/es active Active
- 2013-11-14 EP EP15172149.5A patent/EP2949667B1/en active Active
- 2013-11-14 AR ARP130104196A patent/AR093491A1/es active IP Right Grant
- 2013-11-14 KR KR1020157014594A patent/KR20150084028A/ko active Application Filing
- 2013-11-14 PL PL13798483T patent/PL2920208T3/pl unknown
- 2013-11-14 CA CA3204343A patent/CA3204343A1/en active Pending
- 2013-11-14 US US14/079,686 patent/US9758592B2/en active Active
- 2013-11-14 SG SG11201502629TA patent/SG11201502629TA/en unknown
- 2013-11-14 KR KR1020227004696A patent/KR102563030B1/ko active IP Right Grant
- 2013-11-14 EA EA202190266A patent/EA202190266A1/ru unknown
- 2013-11-14 EP EP13798483.7A patent/EP2920208B1/en active Active
- 2013-11-14 MX MX2015006112A patent/MX2015006112A/es active IP Right Grant
- 2013-11-14 CN CN201811342204.8A patent/CN109485728A/zh active Pending
- 2013-11-14 SG SG10201804124XA patent/SG10201804124XA/en unknown
- 2013-11-14 JP JP2015542760A patent/JP6668074B2/ja active Active
- 2013-11-14 CN CN201380059198.4A patent/CN104797598B/zh active Active
-
2015
- 2015-04-12 IL IL238176A patent/IL238176B/en active IP Right Grant
- 2015-04-15 ZA ZA2015/02538A patent/ZA201502538B/en unknown
- 2015-05-14 MX MX2019015887A patent/MX2019015887A/es unknown
- 2015-11-26 HK HK15111643.1A patent/HK1211036A1/xx unknown
-
2016
- 2016-03-07 HK HK16102584.0A patent/HK1214612A1/zh unknown
-
2017
- 2017-09-11 US US15/700,404 patent/US20180118852A1/en not_active Abandoned
-
2018
- 2018-09-20 JP JP2018175921A patent/JP6856593B2/ja active Active
- 2018-10-23 AU AU2018253474A patent/AU2018253474B2/en active Active
-
2020
- 2020-06-10 IL IL275270A patent/IL275270B/en unknown
- 2020-09-18 US US17/025,656 patent/US20210009714A1/en active Pending
-
2021
- 2021-01-07 AR ARP210100032A patent/AR121002A2/es unknown
- 2021-04-19 AU AU2021202371A patent/AU2021202371A1/en active Pending
- 2021-07-21 IL IL285015A patent/IL285015A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285015A (en) | Recombinant cell surface capture proteins | |
| HRP20190454T1 (hr) | Rekombinantni faktor viii proteini | |
| IL291571A (en) | cx3cr1 binding polypeptides | |
| HK1209651A1 (en) | Cells for producing recombinant iduronate-2-sulfatase -2- | |
| EP2857033A4 (en) | SKIN-PUNKING PEPTIDE | |
| GB201220474D0 (en) | Polypeptides | |
| EP2812347A4 (en) | AUTOPHAGIA-INDUCING PEPTIDE | |
| PL2714888T3 (pl) | Rekombinowane drożdże | |
| SG11201404180RA (en) | Cho-gmt recombinant protein expression | |
| GB201200555D0 (en) | Peptide | |
| GB201220899D0 (en) | CD44v6-derived pegylated peptides | |
| GB201223114D0 (en) | Novel peptide | |
| EP2891663A4 (en) | PEPTIDE DERIVED FROM PSF1 | |
| HK1211952A1 (en) | Recombinant protein | |
| GB201210286D0 (en) | Recombinant polypeptide | |
| GB201112985D0 (en) | Polypeptide | |
| GB201112849D0 (en) | Polypeptide | |
| GB201106130D0 (en) | Polypeptide | |
| GB201203941D0 (en) | Polypeptide detection | |
| GB201204065D0 (en) | Fusion polypeptide | |
| GB201103967D0 (en) | Polypeptide detection | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201200623D0 (en) | Peptide | |
| GB201200624D0 (en) | Peptide |